DiaMedica Therapeutics DMAC 深 沪
已收盘 06-12 16:00:00 美东时间
5.65
+0.190
+3.48%
华盛通- 最 高5.73
- 今 开5.49
- 成交量 10.50万股
- 最 低 5.38
- 昨 收 5.46
- 总市值 3.04亿
- 52周最高 10.4195
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 3.475
- 委 比 27.41%
- 总股本 5388.33万
- 历史最高 10.88
- 量 比 0.52
- 振 幅 6.41%
- 历史最低 1.12
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim AnalysisInterim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging
05-20 20:38
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks
Diamedica Therapeutics (($DMAC)) has held its Q4 earnings call. Read on for the...
04-05 08:13
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call
DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call DiaMedica will release its full-year 2025 financial results after the markets close on March 30, 2026. A conference call to discuss the results is scheduled for March 31, 2026, at 7:00 AM CDT, with webcast acc
03-23 20:25
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
03-05 20:38
Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial
Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial DiaMedica Therapeutics Inc. said it received a No Objection Letter from Health Canada clearing its Clinical Trial Application to evaluate DM199 in a Phase 2 trial for early-onset preeclampsia. The company said the clearance allows it to
03-05 20:35
DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences
DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences DiaMedica Therapeutics Inc. said management will participate in three investor conferences in March 2026: a TD Cowen 46th Annual Healthcare Conference fireside chat in Boston on March 2, 2026; a Barclays
02-24 22:23
DiaMedica Therapeutics Raises Capital via Share Offering
Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. On December 19, ...
01-05 22:49
BRIEF-Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update
Dec 18 (Reuters) - DiaMedica Therapeutics Inc DMAC.O: DIAMEDICA THERAPEUTICS PROVIDES DM199 PREECLAMPSIA PROGRAM UPDATE FOLLOWING PRE-IND MEETING WITH FDA DIAMEDICA THERAPEUTICS INC - FDA REQUESTS ADD...
2025-12-18 22:12
